FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Ostrov

Research Profile

Concepts & Ideas

Phenomena

Living Beings

Mouse

Genes & Molecular Sequences

Amino Acid Sequences

Chemicals & Drugs

Anatomy

Procedures

X Ray Crystallography

Co-author Network

Publications

TOP 3
Vita M Golubovskaya; Baotran Ho; Andrew Magis; David A Ostrov; Min Zheng; William G Cance
Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities.
Vita M Golubovskaya; Baotran Ho; Andrew Magis; David A Ostrov; Nadia L Palma; Min Zheng; William G Cance
A Small-molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK and Mdm-2 Interaction, and Blocks Breast and Colon Tumorigenesis in vivo.
Lilibeth A Salvador; Kanchan Taori; Jason S Biggs; Jean Jakoncic; David A Ostrov; Valerie J Paul; Hendrik Luesch
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Ostrov (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vita M Golubovskaya; Baotran Ho; Andrew Magis; David A Ostrov; Min Zheng; William G Cance
Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities.
Anti-cancer agents in medicinal chemistry 2013;13(4):546-54.
2013: Vita M Golubovskaya; Baotran Ho; Andrew Magis; David A Ostrov; Nadia L Palma; Min Zheng; William G Cance
A Small-molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK and Mdm-2 Interaction, and Blocks Breast and Colon Tumorigenesis in vivo.
Anti-cancer agents in medicinal chemistry 2013;13(4):532-45.
2013: Lilibeth A Salvador; Kanchan Taori; Jason S Biggs; Jean Jakoncic; David A Ostrov; Valerie J Paul; Hendrik Luesch
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
Journal of medicinal chemistry 2013;56(3):1276-90.
2012: Roland W Herzog; David A Ostrov
Immunology. A decorated virus cannot hide.
Science (New York, N.Y.) 2012;338(6108):748-9.
2012: Yuri A Pompeu; Jon D Stewart; Simon Mallal; Bjoern Peters; Elizabeth Phillips; David A Ostrov
The structural basis of HLA-associated drug hypersensitivity syndromes.
Immunological reviews 2012;250(1):158-66.
2012: Deniz A Ucar; Maria Zajac-Kaye; William G Cance; Audrey Cox; Timothy J Garrett; Elena Kurenova; Nicholas Lawrence; Nicole A Massoll; Carl Nyberg; David A Ostrov; Said M Sebti; Steven N Hochwald
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
Cell cycle (Georgetown, Tex.) 2012;11(17):3250-9.
2012: David A Ostrov; Soren Buus; Cesar Augusto F de Oliveira; A Michelle English; Barry J Grant; Howard M Grey; Mikkel Harndahl; Donald F Hunt; Jean Jakoncic; Shun Lu; Andrew Lucas; Simon Mallal; Hu Mei; Carla Oseroff; Elizabeth Phillips; Yuri A Pompeu; Alessandro Sette; Jeffrey Shabanowitz; Leming Shi; John Sidney; Scott Southwood; Amanda Wriston; Lun Yang; Bjoern Peters
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(25):9959-64.
2012: Albert L Shroads; David A Wagner; David Weithorn; John R Bullock; Bonnie S Coats; Yan Gong; Julie A Johnson; Tracie L Kurtz; Taimour Langaee; David A Ostrov; Peter W Stacpoole
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.
Journal of clinical pharmacology 2012;52(6):837-49.
2012: Edgardo J Toro; Shannon M Wallet; Thomas J Wronski; Jian Zuo; Victor Arana-Chavez; Vivian Bradaschia-Correa; Aliana R Caridad; Dana Catalfamo; John K Neubert; David A Ostrov; L Shannon Holliday
Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.
The Journal of biological chemistry 2012;287(21):17894-904.
2012: Vita M Golubovskaya; Baotran T Ho; Grace Huang; Christopher P Johnson; Andrew Magis; Carl Nyberg; David A Ostrov; Michael Yemma; Min Zheng; Sheila Figel; Irwin H Gelman; William G Cance
A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
Carcinogenesis 2012;33(5):1004-13.
2012: Robert N Haire; Gary W Litman; Ronda T Litman; M Gail Mueller; Marci L O'Driscoll; David A Ostrov; Poem M Turner; John P Cannon; Jeffrey A Yoder
Genomic and functional characterization of the diverse immunoglobulin domain-containing protein (DICP) family.
Genomics 2012;99(5):282-91.
2012: Edgardo J Toro; Thomas J Wronski; David A Ostrov; L Shannon Holliday
Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor.
Current protein & peptide science 2012;13(2):180-91.
2012: Ahu Demir; Tomozumi Imamichi; Andrew Magis; Raphael M Oguariri; David A Ostrov; Ben M Dunn
Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Antiviral therapy 2012;17(5):883-92.
2011: Lidia V Kulemina; David A Ostrov
Prediction of off-target effects on angiotensin-converting enzyme 2.
Journal of biomolecular screening 2011;16(8):878-85.
2011: Deniz A Ucar; Audrey Cox; Di-Hua He; Elena Kurenova; David A Ostrov; Steven N Hochwald
A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
Anti-cancer agents in medicinal chemistry 2011;11(7):629-37.
2011: Takashi Hamazaki; Wai-Yee Leung; Brian D Cain; David A Ostrov; Peter E Thorsness; Naohiro Terada
Functional expression of human adenine nucleotide translocase 4 in Saccharomyces cerevisiae.
PloS one 2011;6(4):e19250.
2011: Aruna S Jaiswal; Sanjeev Banerjee; Ritu Aneja; Asfar S Azmi; David A Ostrov; Satya Narayan
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.
PloS one 2011;6(2):e16691.
2010: John P Cannon; Larry J Dishaw; Robert N Haire; Ronda T Litman; David A Ostrov; Gary W Litman
Recognition of additional roles for immunoglobulin domains in immune function.
Seminars in immunology 2010;22(1):17-24.
2010: Donghang Zheng; Vita M Golubovskaya; Elena Kurenova; Cheng Wood; Nicole A Massoll; David A Ostrov; William G Cance; Steven N Hochwald
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.
Molecular carcinogenesis 2010;49(2):200-9.
2009: Aruna S Jaiswal; Sanjeev Banerjee; Harekrushna Panda; Charles D Bulkin; Tadahide Izumi; Asfar S Azmi; David A Ostrov; Satya Narayan
A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.
Molecular cancer research : MCR 2009;7(12):1973-83.
2009: Donghang Zheng; Elena Kurenova; Deniz Ucar; Vita M Golubovskaya; Andrew Magis; David A Ostrov; William G Cance; Steven N Hochwald
Targeting of the protein interaction site between FAK and IGF-1R.
Biochemical and biophysical research communications 2009;388(2):301-5.
2009: David A Ostrov; Andrew T Magis; Thomas J Wronski; Edward Chan; Edgardo J Toro; Richard E Donatelli; Kristen Sajek; Ireni N Haroun; Michael I Nagib; Ana Piedrahita; Ashley Harris; L Shannon Holliday
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
Journal of medicinal chemistry 2009;52(16):5144-51.
2009: Anderson J Ferreira; Vinayak Shenoy; Yoriko Yamazato; Srinivas Sriramula; Joseph Francis; Lihui Yuan; Ronald K Castellano; David A Ostrov; S Paul Oh; Michael J Katovich; Mohan K Raizada
Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.
American journal of respiratory and critical care medicine 2009;179(11):1048-54.
2009: L Shannon Holliday; David A Ostrov; T J Wronski; Calogero Dolce
Osteoclast polarization and orthodontic tooth movement.
Orthodontics & craniofacial research 2009;12(2):105-12.
2008: Issam McDoom; Xianyue Ma; Annet Kirabo; Kuang-Yung Lee; David A Ostrov; Peter P Sayeski
Identification of tyrosine 972 as a novel site of Jak2 tyrosine kinase phosphorylation and its role in Jak2 activation.
Biochemistry 2008;47(32):8326-34.
2008: Jacqueline Sayyah; Andrew Magis; David A Ostrov; Robert W Allan; Raul C Braylan; Peter P Sayeski
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.
Molecular cancer therapeutics 2008;7(8):2308-18.
2008: Syed M Noorwez; David A Ostrov; J Hugh McDowell; Mark P Krebs; Shalesh Kaushal
A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin.
Investigative ophthalmology & visual science 2008;49(7):3224-30.
2008: Andrew T Magis; Kate M Bailey; Elena Kurenova; José A Hernández Prada; William G Cance; David A Ostrov
Crystallization of the focal adhesion kinase targeting (FAT) domain in a primitive orthorhombic space group.
Acta crystallographica. Section F, Structural biology and crystallization communications 2008;64(Pt 6):564-6.
2008: Jose A Hernandez Prada; Sandra L Madden; David A Ostrov; Maria A Hernandez
Molecular modeling optimization of anticoagulant pyridine derivatives.
Journal of molecular graphics & modelling 2008;26(8):1365-9.
2008: José A Hernández Prada; Anderson J Ferreira; Michael J Katovich; Vinayak Shenoy; Yanfei Qi; Robson Augusto Souza Santos; Ronald K Castellano; Andrew J Lampkins; Vladimir Gubala; David A Ostrov; Mohan K Raizada
Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents.
Hypertension 2008;51(5):1312-7.
2007: David A Ostrov; José A Hernández Prada; Robert N Haire; John P Cannon; Andrew T Magis; Kate Bailey; Gary W Litman
Crystallization and X-ray diffraction analysis of a novel immune-type receptor from Ictalurus punctatus and phasing by selenium anomalous dispersion methods.
Acta crystallographica. Section F, Structural biology and crystallization communications 2007;63(Pt 12):1035-7.
2007: David A Ostrov; José A Hernández Prada; Patrick E Corsino; Kathryn A Finton; Nhan Le; Thomas C Rowe
Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening.
Antimicrobial agents and chemotherapy 2007;51(10):3688-98.
2007: Michael D Godeny; Jacqueline Sayyah; Dannielle VonDerLinden; Melissa Johns; David A Ostrov; Jennifer Caldwell-Busby; Peter P Sayeski
The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.
Cellular signalling 2007;19(3):600-9.
2007: David A Ostrov; C L Barnes; L E Smith; S Binns; Todd Brusko; Aaron Clifford Brown; Patrick Quint; Sally A Litherland; D C Roopenian; Kenneth A Iczkowski
Characterization of HKE2: an ancient antigen encoded in the major histocompatibility complex.
Tissue antigens 2007;69(2):181-8.
2007: Gary W Litman; John P Cannon; Larry Dishaw; Robert N Haire; Donna D Eason; Jeffrey A Yoder; Jose Hernandez Prada; David A Ostrov
Immunoglobulin variable regions in molecules exhibiting characteristics of innate and adaptive immune receptors.
Immunologic research 2007;38(1-3):294-304.
2006: José A Hernández Prada; Robert N Haire; Marc Allaire; Jean Jakoncic; vivian stojanoff; John P Cannon; Gary W Litman; David A Ostrov
Ancient evolutionary origin of diversified variable regions demonstrated by crystal structures of an immune-type receptor in amphioxus.
Nature immunology 2006;7(8):875-82.
2005: Eric M Sandberg; Xianyue Ma; Kai He; Stuart J Frank; David A Ostrov; Peter P Sayeski
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].
Journal of medicinal chemistry 2005;48(7):2526-33.
2004: Matthew Huentelman; Jasenka Zubcevic; José A Hernández Prada; Xiaodong Xiao; Dimiter S Dimitrov; Mohan K Raizada; David A Ostrov
Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor.
Hypertension 2004;44(6):903-6.
2004: Jeffrey A Yoder; Ronda T Litman; M Gail Mueller; Salil Desai; Kimberly P Dobrinski; Jennifer S Montgomery; Matthew P Buzzeo; Tatsuya Ota; Chris T Amemiya; Nikolaus S Trede; Sheng Wei; Julie Y Djeu; Sean Humphray; Kerstin Jekosch; Jose A Hernandez Prada; David A Ostrov; Gary W Litman
Resolution of the novel immune-type receptor gene cluster in zebrafish.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(44):15706-11.
2004: José A Hernández Prada; Robert N Haire; John P Cannon; Gary W Litman; David A Ostrov
Crystallization and preliminary X-ray analysis of VCBP3 from Branchiostoma floridae.
Acta crystallographica. Section D, Biological crystallography 2004;60(Pt 11):2022-4.
2004: Eric M Sandberg; Dannielle VonDerLinden; David A Ostrov; Peter P Sayeski
Jak2 tyrosine kinase residues glutamic acid 1024 and arginine 1113 form a hydrogen bond interaction that is essential for Jak-STAT signal transduction.
Molecular and cellular biochemistry 2004;265(1-2):161-9.
2004: M N Becker; William B Greenleaf; David A Ostrov; Richard W Moyer
Amsacta moorei entomopoxvirus expresses an active superoxide dismutase.
Journal of virology 2004;78(19):10265-75.
2004: Donna D Eason; John P Cannon; Robert N Haire; Jonathan P Rast; David A Ostrov; Gary W Litman
Mechanisms of antigen receptor evolution.
Seminars in immunology 2004;16(4):215-26.